Analytical Data
-
Gene name
BCRF1
- Application
-
Alternative Names
20 kDa protein (Protein BCRF1) (vIL-10)
-
Species
Epstein-Barr virus
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P03180
-
Expression Region
24-170aa
-
Molecular Weight
24.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BCRF1, a recombinant protein derived from the Epstein-Barr virus (EBV), has garnered significant interest in immunology and virology research due to its unique role in modulating immune responses. This protein is known to function as an influential viral gene product that aids in the establishment and maintenance of EBV latency by inhibiting host immune mechanisms, particularly through the downregulation of major histocompatibility complex (MHC) class I molecules. As a result, BCRF1 allows infected cells to evade detection by CD8+ cytotoxic T lymphocytes, thereby facilitating viral persistence and contributing to EBV-associated diseases, including various lymphomas and nasopharyngeal carcinoma. Research on BCRF1 has expanded to explore its potential implications in therapeutic interventions, vaccines, and understanding immune evasion strategies employed by viruses. Furthermore, its structure and function have become vital in developing novel treatments against EBV and related malignancies. Studies focusing on the interactions of BCRF1 with immune cells and its impact on the immune landscape are crucial, as they may provide insights into designing targeted therapies and improving vaccine strategies against EBV-related pathologies. Thus, BCRF1 serves as a critical focal point in viral immunology, offering pathways for innovative research endeavors aimed at combatting viral infections and associated tumorigenesis.
